<DOC>
	<DOCNO>NCT01175109</DOCNO>
	<brief_summary>This multi-center study ass safety determine maximum tolerate dose combination imatinib LBH589 patient newly diagnose recurrent chordoma . For recurrent population , patient require immediate surgical resection eligible . Patients treat 4 cycle , follow surgical resection possible . If indicate , surgery may take place prior completion 4 cycle .</brief_summary>
	<brief_title>Study Imatinib , Platelet-derived Growth Factor Receptor Inhibitor , LBH589 , Histone Deacetylase Inhibitor , Treatment Newly Diagnosed Recurrent Chordoma</brief_title>
	<detailed_description />
	<mesh_term>Chordoma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients great equal 18 year age . Histologically documented diagnosis chordoma At least one measurable site disease ( define Response Evaluation Criteria Solid Tumors , see Appendix 3 ) . Performance status 0,1 , 2 ( ECOG ) ( see Section 6 ) Patients must adequate bone marrow end organ function , define follow : 1 . WBC &gt; 3.0 x 109/L 2 . ANC &gt; 1.5 x 109/L , 3 . Platelets &gt; 100 x 109/L 4 . Hemoglobin &gt; 10 gm/dl 5 . Total bilirubin &lt; 1.5 x ULN ( Does apply patient isolated hyperbilirubinemia ( e.g. , Gilbert 's disease ) grade &lt; 3 . 6 . AST/SGOT ALT/SGPT &lt; 2.5 x UNL 7 . Serum creatinine ≤ 2.5 x ULN 24 hr creatinine clearance ≥ 50ml/min 8 . Serum albumin ≤ 3g/dL 9 . Serum amylase lipase ≤ 1.5 x ULN 10 . Alkaline phosphatase ≤ 2.5 x ULN 11 . Patients must follow laboratory value ( WNL = within normal limit local institution lab ) correct within normal limit supplement prior first dose study medication : 1 . Potassium ( WNL ) 2 . Magnesium ( WNL ) 3 . Phosphorus ( WNL ) 4 . Calcium ( WNL ) Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . A scan performed within 14 day prior registration . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . Patients must interval great equal 3 month completion radiation therapy study entry . Patients must willing participate pharmacokinetic study . Written , voluntary inform consent . Patient receive investigational agent within 28 day first day study drug dose treatment chordoma , unless disease rapidly progress . Patients previously treat imatinib LBH589 ineligible . Patients must enzyme induce anticonvulsant valproic acid , seizure medication HDAC inhibition activity . Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Impaired cardiac function include one following : 1 . Inability monitor QT/QTc interval ECG 2 . Long QT syndrome know family history long QT syndrome . 3 . Clinically significant rest brachycardia ( &lt; 50 beat per minute ) 4 . QTc &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc 5 . Myocardial infarction within 12 month prior start study 6 . Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) 7 . History presence clinically significant ventricular atrial tachyarrhythmias Female patient pregnant breastfeeding . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Patient known brain metastasis Patient know diagnosis human immunodeficiency virus ( HIV ) infection . Patient receive chemotherapy within 4 week ( 6 week nitrosourea mitomycinC ) prior study entry , unless disease rapidly progress . Patient receive concurrent treatment warfarin . Patient previously receive radiotherapy &gt; 25 % bone marrow Patient major surgery within 2 week prior study entry . Patient significant history noncompliance medical regimen inability grant reliable informed consent . Patients may receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition imatinib LBH589 use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Chordoma</keyword>
</DOC>